Lv3
288 积分 2022-04-27 加入
Frontline Treatment of Mantle Cell Lymphoma
1天前
待确认
Frontline management of mantle cell lymphoma
1天前
已关闭
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study
2天前
已完结
Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer
3个月前
已完结
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
3个月前
已完结
Colorectal cancer
3个月前
已完结
Practical Management of Oligometastatic Non–Small-Cell Lung Cancer
3个月前
已完结
Systematic Analysis of the Expression Profile and Prognostic Significance of the IGF2BP Family in Lung Adenocarcinoma
4个月前
已完结
Transcriptome of Breast Tumors With Different Amplification Status of the Long Arm of Chromosome 8
1年前
已完结
Neoadjuvant Chemotherapy Induces the Appearance of New Copy Number Aberrations in Breast Tumor and is Associated with Metastasis
1年前
已完结
General synthesis of monodisperse metal oxide nanoparticle clusters
3个月前
已采纳
A Chemically Functionalizable Nanoporous Material [Cu 3 (TMA) 2 (H 2 O) 3 ] n
2年前
已采纳
Engineering Macrophage Exosome Disguised Biodegradable Nanoplatform for Enhanced Sonodynamic Therapy of Glioblastoma
2年前
已采纳
An action potential initiation mechanism in distal axons for the control of dopamine release
2年前
已采纳
Soft x-ray excitonics
2年前
已采纳
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
2年前
已撤回
Locality-Constrained Collaborative Representation with Multi-resolution Dictionary for Face Recognition
2年前
已采纳
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
2年前
已采纳
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
2年前
已采纳
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
2年前
已采纳
皖公网安备34019202002308
